Managing Clinical Trial Compliance

Intake Questions

1. What types of clinical trials does the institution conduct—investigator-initiated, industry-sponsored, cooperative group, NIH-funded, device trials?
2. How many active protocols are currently enrolling, and how many subjects are enrolled?
3. Does the institution have an FDA-registered IRB, or does it rely on external/central IRBs (per the revised Common Rule single IRB mandate)?
4. What is the institution's FDA inspection history—prior Warning Letters, Form 483 observations, Establishment Inspection Reports?
5. Does the institution have a clinical trial management system (CTMS) for protocol tracking, enrollment monitoring, and regulatory document management?
6. Who serves as the institutional official responsible for human subjects protection?
7. Does the institution maintain an FWA (Federalwide Assurance) with OHRP, and is it current?
8. How are financial conflicts of interest managed per 42 CFR Part 50 Subpart F (PHS-funded) and FDA 21 CFR Part 54?
9. Does the institution have a research compliance program integrated with the broader organizational compliance program?
10. What adverse event reporting system is in use for clinical trials?

Required Documents

• Active protocol list with enrollment status, sponsor, IND/IDE numbers
• IRB roster and FWA documentation
• Investigator regulatory binders (Form FDA 1572, CVs, training records, financial disclosures)
• Informed consent form templates and IRB-approved versions
• FDA correspondence (Warning Letters, Form 483s, inspection reports)
• Standard operating procedures for research operations
• Adverse event reporting policies and procedures
• Financial conflict of interest policies and disclosure forms
• Clinical trial agreements and budgets
• Research compliance training records (GCP, HIPAA for research, protocol-specific)
• DSMB/DMC charters and meeting minutes (if applicable)

Step 1 — Investigator Regulatory Compliance

Evaluate compliance with investigator obligations:

• Form FDA 1572 (Statement of Investigator): Verify current, accurate 1572 for each investigator for each IND study. The 1572 commits the investigator to conducting the study per the protocol, investigational plan, and applicable regulations. Verify all sub-investigators are listed or have been added via protocol amendments.
• Investigator Qualifications: Confirm investigators have training and experience appropriate to the investigation. Verify GCP training is current (within 3 years per institutional policy and sponsor requirements). Verify CITI or equivalent human subjects protection training.
• Financial Disclosure: Verify FDA financial disclosure (21 CFR Part 54) forms are current for investigators and sub-investigators for industry-sponsored studies. For PHS-funded research, verify compliance with 42 CFR Part 50 Subpart F financial conflict of interest requirements.
• Protocol Adherence: Assess systems for monitoring protocol compliance—are visits conducted per protocol windows, procedures performed per protocol, and eligibility criteria verified before enrollment?
• Drug/Device Accountability: For IND studies, verify investigational product accountability records (receipt, dispensing, return, destruction). For IDE studies, verify device tracking and accountability per 21 CFR Part 812.
• Record Retention: Confirm trial records are retained for the required period—2 years after IND closure or marketing application approval, or as specified by the sponsor/FDA.

Step 2 — IRB Compliance Assessment

Evaluate IRB operations against 21 CFR Part 56 and 45 CFR Part 46:

• IRB Composition: Verify IRB membership meets regulatory requirements—at least five members with varying backgrounds, at least one non-scientist, at least one unaffiliated member, and expertise adequate to review proposed research.
• Initial Review: Verify all research involving human subjects receives prospective IRB review and approval before enrollment. Review criteria for approval must include all elements of 45 CFR § 46.111: minimized risks, reasonable risk/benefit ratio, equitable subject selection, informed consent, data monitoring, privacy protections, and additional protections for vulnerable populations.
• Continuing Review: Confirm continuing review is conducted at intervals appropriate to the degree of risk (not less than annually). Verify the IRB reviews: protocol status, enrollment numbers, adverse events, protocol deviations, amendments, and consent form revisions.
• Informed Consent: Verify informed consent documents contain all required elements per 21 CFR § 50.25 and 45 CFR § 46.116—including purpose, procedures, risks, benefits, alternatives, confidentiality, compensation, contacts, and voluntariness statement. For HIPAA-covered entities, verify a separate HIPAA authorization or compound authorization is included.
• Single IRB Mandate: For federally funded multi-site studies, verify compliance with the revised Common Rule requirement for single IRB review (effective January 2020). Assess reliance agreements with the reviewing IRB.
• Vulnerable Populations: Verify additional protections for vulnerable populations—children (Subpart D), pregnant women/fetuses (Subpart B), prisoners (Subpart C), and economically/educationally disadvantaged persons.

Step 3 — Adverse Event Reporting and Safety Monitoring

• AE Reporting Timelines: Verify compliance with adverse event reporting timelines—serious unexpected adverse events must be reported to the IRB per institutional policy (typically within 5 business days for serious, 24 hours for deaths), and to the FDA per IND Safety Reporting requirements (21 CFR § 312.32: 15 calendar days for serious and unexpected, 7 calendar days for fatal or life-threatening).
• DSMB/DMC Oversight: For trials requiring Data Safety Monitoring Boards, verify the DSMB charter is established, meetings occur at protocol-specified intervals, and DSMB recommendations are implemented.
• Protocol Deviations: Verify a system exists for identifying, documenting, and reporting protocol deviations. Distinguish between major deviations (affecting subject safety, data integrity, or rights) requiring immediate IRB notification and minor deviations reported at continuing review.
• Unanticipated Problems: Verify the institution distinguishes between adverse events and "unanticipated problems involving risks to subjects or others" (UPIRSOs) per OHRP guidance, and reports UPIRSOs to the IRB, sponsor, and OHRP as required.
• Safety Reporting to FDA: Confirm IND safety reports (IND Safety Reports, Annual Reports) are submitted per required timelines and format.

Step 4 — Data Integrity and 21 CFR Part 11

• Source Document Verification: Verify source documents support the data entered in case report forms (CRFs). Source documents include medical records, laboratory results, imaging reports, and any original record of clinical findings.
• Electronic Records Compliance: If the institution uses electronic systems for trial data (EDC, EHR-sourced data), verify compliance with 21 CFR Part 11 requirements for electronic records and signatures—system validation, audit trails, access controls, and electronic signature authentication.
• Audit Trail: Confirm electronic systems maintain a complete audit trail showing who made what changes, when, and why. Audit trails must be preserved and available for FDA inspection.
• Data Corrections: Verify data correction procedures follow GCP requirements—original data is not obscured, corrections are dated and initialed (or electronic equivalent), and reasons for changes are documented.
• Essential Documents: Verify the Trial Master File (TMF) and investigator site files contain all ICH E6(R2) essential documents for the current phase of the trial.

Step 5 — FDA Inspection Readiness

Prepare for FDA Bioresearch Monitoring (BIMO) inspections:

• Regulatory Binder Audit: Verify investigator regulatory binders are complete, organized, and current. Key documents: 1572, CV, medical license, GCP training, financial disclosure, IRB approval letters, protocol/amendments, consent forms, FDA correspondence, and delegation of authority log.
• Subject Files: Verify subject files contain signed consent forms (correct IRB-approved version at time of consent), eligibility verification, source documents supporting CRF data, adverse event documentation, and protocol deviation documentation.
• Drug/Device Accountability: Verify investigational product logs are complete and reconcile with dispensing and subject records.
• Staff Preparation: Ensure research staff can explain study procedures, regulatory requirements, and their specific roles when interviewed by FDA investigators. Conduct mock inspections annually.
• Form 483 Response Preparation: Establish a process for responding to FDA Form 483 observations within 15 business days with specific corrective actions, responsible parties, and implementation timelines.

Checkpoint B — Compliance Validation

1. Confirm all active protocols have current IRB approval and all required regulatory documents are in place.
2. Verify investigator regulatory binders are complete for all active investigators.
3. Confirm adverse event reporting timelines are met for all reportable events.
4. Validate informed consent documents contain all required elements and HIPAA authorization where applicable.
5. Verify financial conflict of interest disclosures are current for all investigators.
6. Confirm investigational product accountability records are complete and reconciled.
7. Verify electronic systems meet 21 CFR Part 11 requirements with validated audit trails.
8. Confirm research staff GCP training is current for all personnel listed on the delegation log.

Quality Audit

• All active protocols have current IRB approval documentation
• Form FDA 1572 current and accurate for all investigators on IND studies
• GCP and human subjects protection training current for all research staff
• Financial conflict of interest disclosures current per FDA and PHS requirements
• Informed consent documents contain all required elements per 21 CFR § 50.25 and 45 CFR § 46.116
• HIPAA authorization obtained for all subjects at covered entities
• Adverse event reporting timelines met (15-day/7-day for IND safety reports)
• Protocol deviation documentation complete with IRB notification as required
• Investigational product accountability records complete and reconciled
• Electronic records compliance with 21 CFR Part 11 verified
• Trial Master File/investigator site files contain all ICH E6(R2) essential documents
• FDA inspection readiness verified through mock inspection within past 12 months

Guidelines

• Clinical trial compliance is not optional—FDA has the authority to disqualify investigators, place clinical holds on studies, and reject data from non-compliant sites. These actions can have career-ending consequences for investigators and program-ending consequences for sponsors.
• Informed consent is both a regulatory requirement and an ethical obligation. The consent process must be ongoing, not just a one-time signature event. Subjects must be informed of new information that may affect their willingness to participate.
• The single IRB mandate for federally funded multi-site research requires careful attention to reliance agreements, institutional policies, and communication between the reviewing IRB and relying institutions.
• Financial conflicts of interest must be managed proactively. The appearance of conflict can be as damaging as actual conflict to data credibility and public trust in research.
• 21 CFR Part 11 compliance for electronic records is increasingly scrutinized by FDA. Systems that lack validated audit trails, access controls, or electronic signature authentication put data integrity at risk.
• ICH E6(R2) emphasizes quality-by-design and risk-based monitoring—sponsors and institutions should implement risk assessment at the protocol level and focus monitoring resources on critical data and processes.
• This skill produces regulatory compliance assessment output, not legal advice. Clinical trial compliance decisions should involve qualified regulatory counsel and the institutional official responsible for human subjects protection.